Evidence map›Paper›PMID 30558383›Full record

ReviewMaterials (Basel, Switzerland)2018

The Effect of Surface Treatments on the Degradation of Biomedical Mg Alloys-A Review Paper.

Marcjanna Maria Gawlik, Björn Wiese, Valérie Desharnais, Thomas Ebel, Regine Willumeit-Römer

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Enhanced abrasive-mixed-The International journal, advanced manufacturing technology · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Effect of the Thickness of TiOMaterials (Basel, Switzerland) · 2020
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marcjanna Maria GawlikHelmholtz-Zentrum Geesthacht, Max-Planck-Straße 1, 21502 Geesthacht, Germany. marcjanna.gawlik@hzg.de.
Björn WieseHelmholtz-Zentrum Geesthacht, Max-Planck-Straße 1, 21502 Geesthacht, Germany. bjoern.wiese@hzg.de.ORCID 0000-0003-3094-3803
Valérie DesharnaisHelmholtz-Zentrum Geesthacht, Max-Planck-Straße 1, 21502 Geesthacht, Germany. valerie.desharnais@sympatico.ca.
Thomas EbelHelmholtz-Zentrum Geesthacht, Max-Planck-Straße 1, 21502 Geesthacht, Germany. thomas.ebel@hzg.de.
Regine Willumeit-RömerHelmholtz-Zentrum Geesthacht, Max-Planck-Straße 1, 21502 Geesthacht, Germany. regine.willumeit@hzg.de.ORCID 0000-0002-6004-6946

Funding

Helmholtz Virtual Institute - In vivo studies of biodegradable magnesium-based implant materials VH-VI-523
6 · The paper itself

Abstract

This report reviews the effects of chemical, physical, and mechanical surface treatments on the degradation behavior of Mg alloys via their influence on the roughness and surface morphology. Many studies have been focused on technically-used AZ alloys and a few investigations regarding the surface treatment of biodegradable and Al-free Mg alloys, especially under physiological conditions. These treatments tailor the surface roughness, homogenize the morphology, and decrease the degradation rate of the alloys. Conversely, there have also been reports which showed that rough surfaces lead to less pitting and good cell adherence. Besides roughness, there are many other parameters which are much more important than roughness when regarding the degradation behavior of an alloy. These studies, which indicate the relationship between surface treatments, roughness and degradation, require further elaboration, particularly for biomedical Mg alloy applications.

Indexed as

degradation behaviorMg-alloysroughnesssurface treatments

Identifiers

PMID30558383
PMCPMC6315799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.